CA
DNA icon

Continuum Advisory’s Ginkgo Bioworks DNA Stock Holding History

Continuum Advisory’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$198 Buy
+20
New +$167 ﹤0.01% 1954
2025
Q2 		– Sell
-20
Closed -$114 – 697
2025
Q1 		$114 Hold
20
– – ﹤0.01% 1634
2024
Q4 		$196 Hold
20
– – ﹤0.01% 1816
2024
Q3 		$146 Hold
20
– – ﹤0.01% 1881
2024
Q2 		$267 Hold
20
– – ﹤0.01% 1670
2024
Q1 		$736 Buy
+20
New +$1.03K ﹤0.01% 1526

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Continuum Advisory's DNA Position: Q2 2026 in Review

Continuum Advisory opened a new position in Ginkgo Bioworks (DNA) in Q2 2026: 20 shares worth $198. The stake represents ﹤0.01% of the portfolio and ranks #1954 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in DNA as recently as Q1 2025.

Continuum Advisory first reported a position in DNA in Q1 2024 and has held it in 6 quarters since. The position peaked at $736 in Q1 2024. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Continuum Advisory held 20 shares of Ginkgo Bioworks worth $198 as of Q2 2026.
  • Ginkgo Bioworks was a new Continuum Advisory position in Q2 2026.
  • Ginkgo Bioworks made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1954 holding.
  • Continuum Advisory first reported a position in Ginkgo Bioworks in Q1 2024 and has held it in 6 quarters since.
  • Continuum Advisory's Ginkgo Bioworks position peaked at $736 in Q1 2024.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.